TY - JOUR
T1 - Corrigendum
T2 - Metastatic extramammary Paget's disease: Pathogenesis and novel therapeutic approach [Front Oncol, 8, (2018), (38)] doi: 10.3389/fonc.2018.00038
AU - Fukuda, Keitaro
AU - Funakoshi, Takeru
N1 - Publisher Copyright:
© 2018 Fukuda and Funakoshi.
PY - 2018/3/12
Y1 - 2018/3/12
N2 - In the published article, there was an error in the number of ongoing clinical trial for HER2-positive unresectable or metastatic EMPD "(UMIN-000006629)". Instead of "(UMIN-000006629)", it should be "(UMIN000021311)". The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
AB - In the published article, there was an error in the number of ongoing clinical trial for HER2-positive unresectable or metastatic EMPD "(UMIN-000006629)". Instead of "(UMIN-000006629)", it should be "(UMIN000021311)". The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
KW - Anti-PD-1 antibody
KW - CD163+M2 macrophage
KW - CXCR4-stromal cell-derived factor-1 axis
KW - HER2-PI3K/ERK signaling
KW - Lymphangiogenesis
KW - Metastatic extramammary Paget's disease
KW - Mismatch-repair deficient
KW - Receptor activator of nuclear factor kappa-B ligand-RANK signaling
UR - http://www.scopus.com/inward/record.url?scp=85043518919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043518919&partnerID=8YFLogxK
U2 - 10.3389/fonc.2018.00047
DO - 10.3389/fonc.2018.00047
M3 - Comment/debate
AN - SCOPUS:85043518919
SN - 2234-943X
VL - 8
JO - Frontiers in Oncology
JF - Frontiers in Oncology
IS - MAR
M1 - 47
ER -
